Real‐World Usage and Outcomes of Different Siltuximab Dosing Frequency in Idiopathic Multicentric Castleman Disease

Documenti analoghi

• Comparative Safety of Tocilizumab and Siltuximab in Castleman Disease: Pharmacovigilance Study
  di: Yoshito Nishimura, et al.
  Pubblicazione: (2025)
• Cryoablation for unresectable unicentric Castleman disease
  di: Yoshito Nishimura, et al.
  Pubblicazione: (2024)
• International Consensus Histopathological Criteria for Subtyping Idiopathic Multicentric Castleman Disease Based on Machine Learning Analysis
  di: Midori Filiz Nishimura, et al.
  Pubblicazione: (2025)
• Idiopathic Multicentric Castleman Disease— TAFRO : A Potentially Curable Disease?
  di: Lu Zhang, et al.
  Pubblicazione: (2026)
• The Evolution and Recent Advances in Diagnostic Criteria for Idiopathic Multicentric Castleman Disease
  di: FNU Alnoor, et al.
  Pubblicazione: (2025)